Hemostemix Transforming Lives - The Autologous Stem Cell Pioneer
Through seven clinical trials of ACP-01, in 318 subjects, for
Angina (24), Ischemic and Dilated Cardiomyopathy (41, 106, 54),
Peripheral Arterial Disease and Chronic Limb Threatening
Ischemia (6, 20, 67), Hemostemix has pioneered and scientifically
proven ACP-01 to be safe and statistically efficacious. ACP-01
increases circulation where the body signals that need. It
increases cardiac ejection fraction and exercise capacity. It saves
limbs from amputation.
Additionally, after one treatment, ACP-01 reversed the early onset
of vascular dementia. Mrs. L’s results have persisted for 10 years
and counting, which is why we are completing a Phase I clinical
trial.
